Scalper1 News
Big pharma Eli Lilly (LLY) said Monday that its drug candidate reduced blood sugar in diabetics more than another leading treatment. The company’s stock rose a fraction on the stock market today. The phase-three clinical trial showed Lilly’s basal insulin peglispro (BIL) outperformed Sanofi’s (SNY) Lantus in patients with type 2 diabetes, though it did not yet release the exact numbers. Lilly also said patients on BIL showed less weight gain than Scalper1 News
Scalper1 News